- Home
- NKSH vs IPHA Comparison
NKSH vs IPHA Comparison
Compare NKSH & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | IPHA |
|---|---|---|
| Founded | 1891 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.2M | 174.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NKSH | IPHA |
|---|---|---|
| Price | $33.17 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 15.1K | ★ 26.4K |
| Earning Date | 01-22-2026 | 09-17-2025 |
| Dividend Yield | ★ 4.57% | N/A |
| EPS Growth | ★ 41.35 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $51,980,000.00 | $14,839,695.00 |
| Revenue This Year | $2.95 | $22.29 |
| Revenue Next Year | $9.97 | $43.90 |
| P/E Ratio | $16.16 | ★ N/A |
| Revenue Growth | ★ 19.63 | N/A |
| 52 Week Low | $23.75 | $1.60 |
| 52 Week High | $35.00 | $2.63 |
Technical Indicators
Market Signals| Indicator | NKSH | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 50.72 |
| Support Level | $33.39 | $1.70 |
| Resistance Level | $35.00 | $1.83 |
| Average True Range (ATR) | 0.83 | 0.09 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 25.51 | 62.90 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.